Gastric residence systems comprising buprenorphine and naloxone
AssigneeLyndra Therapeutics, Inc.
InventorsNupura BHISE, Jeffrey KATSTRA, David ALTREUTER
Life of this patent
Estimating the term…
Loading patent…
AssigneeLyndra Therapeutics, Inc.
InventorsNupura BHISE, Jeffrey KATSTRA, David ALTREUTER
Estimating the term…
Provided are gastric residence systems comprising at least one co-extruded drug-eluting component comprising a carrier polymer, buprenorphine or a salt thereof, and naloxone or a salt thereof, and a rate-modulating release film coating the at least one co-extruded drug-eluting component. The gastric residence systems comprising at least one co-extruded drug-eluting component are configured to be maintained within a stomach of a human body for at least 48 hours and to release buprenorphine for at least 48 hours, such that the at least one co-extruded drug eluting component with the rate-modulating release film is configured to release at least 10% of the buprenorphine or the salt thereof after the first 24 hours of residence within the stomach and at least 10% of the naloxone or the salt thereof after the first 24 hours of residence within the stomach.
A gastric residence system comprising:
A gastric residence system comprising:
A gastric residence system comprising:
A method of making a gastric residence system comprising:
A method of making a gastric residence system comprising:
Dependencies are inferred from the claim text.